Synthetic Biologics SYN 深 沪
等待开盘 11-04 09:30:00 美东时间
1.02
0.000
0.00%
华盛通- 最 高--
- 今 开--
- 成交量 0股
- 最 低 --
- 昨 收 1.02
- 总市值 1616.10万
- 52周最高 113.75
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 24.25
- 委 比 0.00%
- 总股本 1584.41万
- 历史最高 37800.00
- 量 比 0
- 振 幅 0.00%
- 历史最低 38.00
- 每 手 1
- 风险率 0.00%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多SynAct Pharma’s Q3 2025 Interim Report Highlights
The latest announcement is out from SynAct Pharma AB ( ($SE:SYNACT) ). SynAct P...
10-30 16:21
Syndax to Announce Third Quarter 2025 Financial Results and Host Conference Call and Webcast on November 3, 2025
Syndax Pharmaceuticals announced it will report its third quarter 2025 financial results and provide a business update on November 3, 2025. The company's management will host a conference call and live audio webcast at 4:30 p.m. ET on that day. The webcast and slides can be accessed through the company's website or via provided dial-in numbers. A replay will be available on the Investors section of the website 24 hours after the call and will rem...
10-27 11:00
Syngene Enhances Biologics Facility with ADC Bioconjugation
Syngene International Ltd. ( ($IN:SYNGENE) ) has shared an announcement. Syngen...
10-24 01:13
Synsam AB Executes Share Buy-Back to Adjust Capital Structure
Synsam AB ( ($SE:SYNSAM) ) has issued an announcement. Synsam AB has repurchase...
10-21 00:32
Syngene Launches ‘Saksham Niveshak’ Campaign to Secure Shareholder Dividends
Syngene International Ltd. ( ($IN:SYNGENE) ) has provided an update. Syngene In...
10-19 00:23
MNC半年豪掷107亿美元，这个脂肪肝靶点终于爆了
文 | 医曜 早在2023年底的时候，我们就曾推断：脂肪肝将是减肥药后的下一个千亿战场。如今MNC正用真金白银，让这一推断渐渐落地。 10月9日，诺和诺德突然...
10-18 12:37
Novo Nordisk To Acquire Liver Disease Focused Akero Therapeutics For Around $5 Billion
Novo Nordisk to buy Akero Therapeutics for up to $5.2 billion, adding EFX, a late-stage MASH treatment candidate, to its metabolic disease portfolio.
10-09 21:10
Akero(AKRO.US)盘前大涨！获诺和诺德(NVO.US)52亿美元收购
诺和诺德(NVO.US)周四宣布已达成最终协议，将收购美国生物制药公司Akero Therapeutics(AKRO.US)，交易总价最高达52亿美元。
10-09 20:50
诺和诺德52亿美元买下潜力新药，抢占下一个万亿病症市场
①诺和诺德以47亿美元现金和5亿美元“或有价值权”收购Akero，交易总价最高达52亿美元； ②Akero药物efruxifermin正处于III期临床开发阶段，有望治疗由代谢功能障碍相关脂肪性肝炎引起的中度至晚期肝纤维化和肝硬化患者。
10-09 20:31
每日数字货币动态汇总（2025-10-09）
小程序：每日数字货币动态汇总 1. 分析师：比特币短期持有者过去一季度持有量增加55.9万枚 CryptoQuant分析师Axel在X平台上发文表示：“在过去一...
10-09 10:46
